Asset Management One Co. Ltd. Sells 2,450 Shares of Cencora, Inc. (NYSE:COR)

Asset Management One Co. Ltd. cut its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,882 shares of the company's stock after selling 2,450 shares during the period. Asset Management One Co. Ltd. owned approximately 0.05% of Cencora worth $22,439,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Swedbank AB grew its holdings in shares of Cencora by 2.3% in the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock worth $313,863,000 after acquiring an additional 31,104 shares during the last quarter. Vontobel Holding Ltd. increased its stake in Cencora by 1.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company's stock worth $957,000 after purchasing an additional 58 shares in the last quarter. Good Life Advisors LLC increased its stake in Cencora by 81.7% in the 3rd quarter. Good Life Advisors LLC now owns 3,050 shares of the company's stock worth $687,000 after purchasing an additional 1,371 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Cencora by 1.1% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,285 shares of the company's stock worth $6,366,000 after purchasing an additional 305 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its stake in Cencora by 3.8% in the 3rd quarter. V Square Quantitative Management LLC now owns 3,634 shares of the company's stock worth $818,000 after purchasing an additional 132 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

COR traded up $3.93 on Wednesday, hitting $245.37. The company had a trading volume of 1,553,062 shares, compared to its average volume of 1,509,604. The company's fifty day moving average price is $238.75 and its 200 day moving average price is $237.41. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.26. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock has a market cap of $47.58 billion, a price-to-earnings ratio of 34.90, a price-to-earnings-growth ratio of 1.30 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analysts Set New Price Targets

Several equities analysts have weighed in on COR shares. JPMorgan Chase & Co. lifted their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Robert W. Baird lifted their target price on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. UBS Group lifted their target price on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Finally, Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $277.90.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.